Vaccinations & Immunizations

Pfizer COVID-19 Vaccine Can be Used in Adolescents, FDA Says

by Samantha McGrail

FDA recently expanded the emergency use authorization for the Pfizer COVID-19 vaccine to include adolescents 12 through 15 years of age. The agency amended the original emergency use authorization...

Biden Administration Backs Waiver of COVID-19 Intellectual Property

by Hannah Nelson

United States Trade Representative Katherine Tai announced the Biden-Harris Administration’s support for waiving COVID-19 vaccine intellectual property in order to speed up vaccine distribution...

CVS Goes to Workplace Vaccination Sites to Boost Access

by Samantha McGrail

CVS Health recently announced that it began administering COVID-19 vaccines at workplace vaccination sites to increase access to vaccinations.  The vaccination increase comes on the heels of...

Gavi Secures 500M Doses of Moderna’s COVID-19 Vaccine for COVAX

by Samantha McGrail

Gavi, the Vaccine Alliance, recently announced that it signed an advance purchase agreement with Moderna for 500 million doses of its mRNA COVID-19 vaccine.  The initial supply under the...

Moderna Increases Global 2022 COVID-19 Vaccine Capacity to 3B

by Samantha McGrail

Moderna recently announced that it will increase global 2022 capacity for its COVID-19 vaccine to up to 3 billion doses, boosting production at its owned and partnered manufacturing facilities. The...

FDA Completes Review of J&J Vaccine Manufacturing Facility

by Samantha McGrail

FDA recently completed an inspection of Emergent BioSolutions, a proposed manufacturing facility for Johnson & Johnson’s COVID-19 vaccine.  The agency’s assessments reviewed the...

FDA, CDC Lift Pause of Johnson & Johnson’s COVID-19 Vaccine

by Samantha McGrail

FDA and the CDC recently lifted the pause of the Johnson & Johnson COVID-19 vaccine in the US following a thorough safety review, including two meetings of the CDC’s Advisory Committee of...

Rollout of Johnson & Johnson’s COVID-19 Vaccine Resumes in Europe

by Samantha McGrail

Johnson & Johnson recently announced that the rollout of its COVID-19 vaccine will resume in Europe. The European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment Committee...

Trial Updates from Moderna’s mRNA, RSV Vaccine Candidates

by Samantha McGrail

Moderna recently announced Phase 1 data updates for its RSV vaccine candidate and new seven-month interim Phase 2 data regarding its cytomegalovirus (CMV) vaccine candidate.  Researchers stated...

Roche’s COVID-19 Antibody Cocktail Reduces Symptoms by 81%

by Samantha McGrail

Roche recently confirmed positive results from the Phase 3 trial assessing its COVID-19 antibody cocktail, which aims to reduce coronavirus infection among household contacts of individuals infected...

FDA, CDC Pauses J&J COVID-19 Vaccine Due To Rare Blood Clot Cases

by Hannah Nelson

The CDC and FDA are reviewing data involving six reported cases of a severe and rare kind of blood clot in individuals who received the Johnson & Johnson (Janssen) COVID-19 vaccine. This comes...

Data Reveals High Vaccine Efficacy for Moderna, Pfizer Doses

by Samantha McGrail

The New England Journal of Medicine (NEJM) recently released antibody persistence data six months following the second dose of Moderna’s COVID-19 vaccine, mRNA-1273. As detected by three...

European Countries Suspend Use of AstraZeneca’s COVID-19 Vaccine

by Samantha McGrail

Many European countries, including Germany, France, Italy, and Spain recently suspended the use of AstraZeneca’s COVID-19 vaccine after experts found dangerous blood clots in some vaccine...

J&J Takes Over Vaccine Production at Plant That Spoiled 15M Doses

by Samantha McGrail

The Biden Administration recently appointed Johnson & Johnson to lead COVID-19 vaccine production at a Baltimore manufacturing plant that contaminated 15 million doses of the pharmaceutical...

FDA Makes Revisions to Moderna’s COVID-19 Vaccine Authorization

by Samantha McGrail

FDA recently announced two revisions regarding the number of doses per vial available for Moderna’s COVID-19 vaccine, mRNA-1273. The agency’s first revision clarifies the number of doses...

NIH Launches COVID Variant Trial; Pfizer Releases New Data

by Samantha McGrail

NIH recently announced that it has started a Phase 1 clinical trial of Moderna’s variant-specific COVID-19 vaccine candidate, mRNA-1273.351. Researchers will evaluate the safety and...

Pfizer-BioNTech COVID-19 Vaccine 100% Effective in Adolescents

by Samantha McGrail

Pfizer and BioNTech recently announced that its COVID-19 vaccine, BNT162b2, demonstrated 100 percent efficacy and robust antibody responses in adolescents with or without prior SARS-CoV-2...

Real-World Evidence Confirms Efficiency of mRNA COVID-19 Vaccines

by Samantha McGrail

A new CDC study used real-world evidence to find that mRNA COVID-19 vaccines are highly effective in preventing SARS-CoV-2 infections among healthcare personnel, first responders, and other essential...

Moderna Studies COVID-19 Vaccine Candidate in Pediatric Population

by Samantha McGrail

Moderna recently announced that the first participants were dosed in the Phase 2/3 study of its COVID-19 vaccine candidate, mRNA-1273, in children six months to up to 12 years of age.  The study,...

AstraZeneca COVID-19 Vaccine 76% Effective in Phase 3 Trial

by Samantha McGrail

AstraZeneca recently announced that its COVID-19 vaccine was 76 percent effective against the coronavirus and 100 percent effective at preventing severe disease and hospitalization in a Phase 3...